Who
Hans van Houte
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Nurix Therapeutics.
In numbers
- Trades disclosed
- 187
- Buys
- 0
- Sells
- 35
- Bought
- $0
- Sold
- $5.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Feb 2021
- Last trade
- 4 Aug 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Aug 2026filed 4 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $43K1,794 at $23.89 | filing |
| 4 Aug 2026filed 4 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $73K2,967 at $24.65 | filing |
| 4 Aug 2026filed 4 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $43K1,794 at $23.89 | filing |
| 4 Aug 2026filed 4 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $73K2,967 at $24.65 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,858 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,572 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,858 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,572 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $67K2,845 at $23.38 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,858 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,572 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,858 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,572 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $67K2,845 at $23.38 | filing |
| 5 May 2026filed 5 May 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $223K13,473 at $16.58 | filing |
| 5 May 2026filed 5 May 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,996582 at $17.18 | filing |
News
Nurix Therapeutics (NASDAQ:NRIX) Director Julia Gregory Sells 22,583 Shares of Company StockNRIX · dailypolitical.com · 15 Oct 2026Nurix Therapeutics Q3 2026 Earnings: Key Financials RevealedNRIX · sci-tech-today.com · 13 Oct 2026Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNRIX · manilatimes.net · 12 Oct 2026
0 headlines in the last 90 days name Hans van Houte; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.